Bayer Presents New Subgroup Analyses for KERENDIA® (finerenone) for Chronic Kidney Disease Associated With Type 2 Diabetes With or Without History of Atherosclerotic Cardiovascular DiseaseBusiness Wire • 04/04/22
Windstream Names Buddy Bayer to Lead Combined Enterprise, Wholesale OrganizationBusiness Wire • 03/30/22
Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA® (finerenone) as Well as Oral Factor XIa Inhibitor (asundexian) ProgramBusiness Wire • 03/29/22
Here's Why Bayer Aktiengesellschaft (BAYRY) is a Strong Value StockZacks Investment Research • 03/23/22
Bayer to Sell Its Environmental Science Professional Business to Cinven for 2.6 Billion U.S. DollarsBusiness Wire • 03/10/22
Is Bayer Aktiengesellschaft (BAYRY) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 03/09/22
Bayer Submits Applications in the U.S. and EU for Additional Indication of NUBEQA® (darolutamide)Business Wire • 03/09/22
Bayer Strengthens Company's Government and Industry Affairs Group in Key U.S. Market with Two AppointmentsBusiness Wire • 03/04/22
Bayer Announces Changes in Executive Leadership Team of Crop Science DivisionBusiness Wire • 03/03/22
Bayer Corn Trait Gains EPA Approval: VT4PRO™ with RNAi Technology to Launch in US as Early as 2024Business Wire • 03/02/22
Bayer AG (BAYZF) CEO Werner Baumann on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22